Evaluation of antitumor immunity by a combination treatment of high-dose irradiation, anti-PDL1, and anti-angiogenic therapy in murine lung tumors
Journal
Cancer Immunology, Immunotherapy
Journal Volume
70
Journal Issue
2
Pages
391-404
Date Issued
2021
Author(s)
Pan, C.-K.
Tsai, C.-Y.
Lin, Y.-L.
Shieh, M.-J.
Abstract
C57BL/6 mice implanted in the flank with murine Lewis lung carcinoma cells were randomized into control, anti-angiogenic, anti-PD-L1, radiotherapy (RT), RT + anti-angiogenic, RT + anti-PD-L1, and RT + anti-PD-L1 + anti-angiogenic therapy groups. Immune re
SDGs
Other Subjects
antineoplastic monoclonal antibody; bevacizumab; echo contrast medium; programmed death 1 ligand 1; usphere prime; angiogenesis inhibitor; programmed death 1 receptor; additive effect; animal cell; animal experiment; animal model; animal tissue; antiangio
Publisher
Springer Science and Business Media Deutschland GmbH
Type
journal article